Allele Biotech to Conduct RNAi Screening for NCI | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Allele Biotech on Friday announced that it has signed a contract with the National Cancer Institute to conduct RNAi screening aimed at identifying synthetic targets for killing cancer cells.

The San Diego-based firm will use its high-quality fluorescent proteins, lentivirus systems, and shRNA platform for the project. It noted that the University of Florida is a sub-contractor on the contract.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.